Table 1.
Baseline Patient Characteristics.
| Total (N = 82) | RPF (N = 61) | Placebo (N = 21) | |
|---|---|---|---|
| Age in years, median (range) | 59 (29-75) | 59 (29-75) | 55 (39-70) |
| <65, n (%) | 66 (80) | 48 (79) | 18 (86) |
| ≥65, n (%) | 16 (20) | 13 (21) | 3 (14) |
| Gender, n (%) | |||
| Male | 58 (71) | 45 (74) | 13 (62) |
| Female | 24 (29) | 16 (26) | 8 (38) |
| Cancer stage, n (%) | |||
| Stage I | 5 (6) | 4 (7) | 1 (5) |
| Stage II | 15 (18) | 11 (18) | 4 (19) |
| Stage IIIA | 6 (7) | 4 (7) | 2 (9) |
| Stage IIIB | 14 (17) | 9 (14) | 5 (24) |
| Stage IV | 42 (51) | 33 (54) | 9 (43) |
| Histology, n (%) | |||
| Squamous | 32 (40) | 24 (40) | 8 (38) |
| Non-squamous | 49 (60) | 36 (60) | 13 (62) |
| Chemotherapy scheme, n (%) | |||
| Paclitaxel plus cisplatin (TP) | 48 (59) | 35 (57) | 13 (62) |
| Paclitaxel plus carboplatin (TC) | 34 (41) | 26 (43) | 8 (38) |
| Past chemotherapya, n (%) | |||
| Yes | 34 (41) | 25 (41) | 9 (43) |
| No | 48 (59) | 36 (59) | 12 (57) |
| KPS score, median (range) | 90 (70-100) | 90 (70-90) | 90 (70-100) |
| FACT-L, mean (SD) | |||
| FACT-L total | 89.1 (17.1) | 88.1 (16.8) | 91.9 (18.2) |
| FACT-G total | 70.5 (14.4) | 69.7 (14.4) | 72.7 (14.3) |
| Trial Outcome indexb | 53.6 (11.3) | 52.8 (10.5) | 56.1 (13.3) |
| Lung cancer subscale | 18.6 (4.2) | 18.3 (4.0) | 19.2 (4.8) |
| Physical well-being | 20.8 (4.7) | 20.6 (4.7) | 21.6 (4.7) |
| Social/family well-being | 20.0 (4.9) | 19.9 (4.5) | 20.0 (5.9) |
| Emotional well-being | 15.5 (4.9) | 15.4 (4.9) | 15.8 (4.9) |
| Functional well-being | 14.3 (2.5) | 13.9 (4.9) | 15.2 (6.0) |
Abbreviations: RPF, Reishi & Privet formula; KPS, Karnofsky performance score; FACT-L, Functional Assessment of Cancer Therapy–Lung; FACT-G, FACT-General.
a
Past chemotherapy means whether patients had received any chemotherapy before this study.
b
Trial Outcome Index = physical well-being + functional well-being + lung cancer subscale.